Artan Dozda Metilfenidat ile Tedavi Edilen Bir Erkek Ergende Oluşan Geçici Hematüri

Yıl 2019, Cilt: 24 Sayı: 3, 244 - 247, 24.10.2019

Zeynep Nur Gülle , Murat Coşkun

Öz

In this report we presented the case of an adolescent male who noticed bloody spots on his underwear after the dose increase during his osmotic-controlled release oral delivery systemmethylphenidate (MPH) treatment. This symptom disappeared when the MPH treatment was discontinued, was not reported with atomoxetine monotherapy, but reoccurred with combination treatment using atomoxetine and increased doses of immediate-release MPH. We discussed the clinical picture and the possible pathophysiological mechanisms for this adverse effect.

Anahtar Kelimeler

hematüri, metilfenidat, yan etki

Transient Hematuria in an Adolescent Male Treated with Increased Doses of Methylphenidate

Öz

Here we report a case of an
adolescent boy who developed bloody spots on his underwear with increasing
dosage of osmotic-controlled release oral delivery system (OROS) MPH. This
symptom did not occur with atomoxetine monotherapy but occurred with
atomoxetine and increased dosage of immediate release MPH combination. We plan
to discuss the clinical picture and possible pathophysiological mechanisms of
this adverse effect.

Anahtar Kelimeler

hematuria, methylphenidate, adverse effect

Kaynakça

• 1. Green WH. (2007), Sympathomimetic amines and central nervous system stimulants. Child and adolescent clinical psychopharmacology, 4. ed. Philadelphia. Lippincott Williams & Wilkins
• 2. Coskun M, Zoroglu S. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol. 2008;28:723–725.
• 3. Coskun M, Zoroglu S. A report of two cases of sexual side effects with OROS methylphenidate. J Child Adolesc Psychopharmacol. 2009;19:477–479.
• 4. Coskun M, Adak I. Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2017;37:637-639.
• 5. Coskun M. Methylphenidate induced obsessive-compulsive symptoms treated with sertraline. Bull Clin Psychopharmacol. 2011;21:274-274.
• 6. Coskun M, Adak I, Akaltun I. Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine. J Clin Psychopharmacol. 2014;34: 37-538.
• 7. Coskun M, Kaya I. Painful muscle cramps possibly associated with withdrawal from methylphenidate. J Child Adolesc Psychopharmacol. 2016;26:658-659.
• 8. Adak I, Coskun M. Symptomatic cholelithiasis associated with combined use of methylphenidate and fluoxetine in an otherwise healthy adolescent girl. Bull Clin Psychopharmacol 2017; 27.1:101.
• 9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30: 239–245.
• 10. Avellino GJ, Bose S, Wang DS. Diagnosis and management of hematuria. Surg Clin North Am. 2016;3:503-51.
• 11. Kuperman AA, Yaniv I, Stahl B, Tamary H. Methylphenidate as a possible cause of thrombocytopenia. Ann Pharmacother. 2003;37:1146.
• 12. Prabhuswamy M, Srinath S, Girimaji S, Seshadri S. Methylphenidate and hypertension. J Child Adolesc Psychopharmacol. 2006;6:805-806.
• 13. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology. 2003;3:264-270.
• 14. Yesilkaya B, Alli N, Artuz RF, Ulu E, Kartal D, Cinar SL. The frequency of hematuria in acne vulgaris patients during isotretinoin treatment. Cutan Ocul Toxicol. 2017;1:74-76.
• 15. Taj A, Vijendra D, Shafiq Q, Mohamed I. Carboplatin-induced hematuria in a patient of breast carcinoma. A case report. Am J Ther. 2011;6: e269-e270.